Advanced materials company SiO2 Materials Science has increased the manufacturing capacity of its plastic medical-grade vials to help meet the demand for COVID-19 vaccines.
Australian cancer therapeutics company Affinity Biosciences has discovered potent SARS-CoV-2 antibodies with potential therapeutic applications against the novel coronavirus.
Hansa Biopharma has entered into an agreement with Sarepta Therapeutics for an exclusive worldwide license to develop and promote imlifidase as a pretreatment for gene therapy treatment of Duchenne muscular dystrophy and limb-girdle muscular dystrophy.
Montana-based Inimmune received a $2 million grant from the U.S. National Institute for Allergy and Infectious Diseases to develop novel adjuvant and delivery systems for vaccines.
Luminex has delivered the xMap Intelliflex system, a new version of its multiplexed biological test platform, to several life science partners.
Real estate developer MRA Group is building lab spaces in Philadelphia to meet the region's growing demand for cell and gene therapy.
Johnson & Johnson announced that the European Commission granted marketing authorization for its Janssen Pharmaceutical Ebola vaccine regimen for the prevention of Ebola virus disease.
Lysogene has inked a research agreement with Yeda Research and Development, the commercial arm of the Weizmann Institute of Science for novel gene therapy.
Intravacc has entered a strategic partnership with CimCure for in-licensing of CimCure's iBoost technology for cancer immunotherapy vaccines and a COVID-19 vaccine.
Golden Biotechnology (GoldenBiotech), a Taiwanese-based biopharmaceutical company, has received U.S. Food and Drug Administration approval to begin a phase II clinical trial of antroquinonol on COVID-19 patients in the U.S.